{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:02:30Z","timestamp":1792245750587,"version":"4.4.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013543","name":"European Society of Paediatric Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Ministry of Science and Innovation\u2014Instituto de Salud Carlos III and Fondos FEDER","award":["JR22\/00044"],"award-info":[{"award-number":["JR22\/00044"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Isavuconazole (ISA) has been recently approved for the treatment of invasive aspergillosis and mucormycosis in patients aged &amp;gt;1\u2005year. Prior to this approval, it was used in paediatric patients under compassionate use. The objective of this study is to describe the experience with ISA use in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A descriptive, retrospective, multicentre study conducted in nine Spanish hospitals, including patients aged \u226418\u2005years who received \u22657\u2005days of ISA between 2018 and 2023. Therapeutic drug monitoring (TDM) was performed with pre-dose [trough concentration (Ctrough)] levels measured according to local protocols. A therapeutic range of 2.5\u20135\u2005mg\/L was used for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 107 patients (median age: 11\u2005years, 56% male) were included. ISA was used as a treatment (95 patients), mostly as second-line therapy (64 patients, 67%), due to toxicity from previous antifungals (27 patients, 42%). Of 53 patients with proven\/probable invasive fungal disease (IFD), 32 (60%) showed a favourable response and 21 (40%) died, 13 due to IFD. Twelve patients received ISA as prophylaxis and none developed breakthrough IFD. Overall, 27\/107 (25%) patients experienced adverse effects, the most common being hepatotoxicity, with 10 requiring discontinuation. TDM was performed in 76\/95 patients (80%), revealing 59% of Ctrough values outside the therapeutic range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ISA appears to be a safe and effective option for treating IFD in children, especially when first-line agents have failed or caused excessive toxicity. Although no correlation between Ctrough and clinical outcomes was observed, the significant proportion of patients with out-of-range Ctrough emphasizes the need for TDM in paediatrics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf394","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:10:20Z","timestamp":1759925420000},"source":"Crossref","is-referenced-by-count":6,"title":["Real-life use of isavuconazole in Spanish children and adolescents"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2035-8291","authenticated-orcid":false,"given":"Natalia","family":"Mendoza-Palomar","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies Unit, Children\u2019s Hospital, Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]},{"name":"Infection and Immunity in Pediatric Patients Research Group, Vall d\u2019Hebron Research Institute , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2115-1695","authenticated-orcid":false,"given":"Silvia","family":"Sim\u00f3 Nebot","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Systemic Inflammatory Response in Paediatrics, Paediatric Infectious Diseases Department, Institut de Recerca Sant Joan de D\u00e9u, Hospital Sant Joan de D\u00e9u , Barcelona ,","place":["Spain"]},{"name":"Centre for Biomedical Network Research on Epidemiology and Public Health (CIBERESP) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-4530","authenticated-orcid":false,"given":"Laura","family":"Roig-Soria","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies Unit, Children\u2019s Hospital, Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]},{"name":"Infection and Immunity in Pediatric Patients Research Group, Vall d\u2019Hebron Research Institute , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-1594","authenticated-orcid":false,"given":"Laura","family":"Alonso Garc\u00eda","sequence":"additional","affiliation":[{"name":"Infection and Immunity in Pediatric Patients Research Group, Vall d\u2019Hebron Research Institute , Barcelona ,","place":["Spain"]},{"name":"Paediatric Haematology and Oncology Department, Stem Cell Transplant Unit, Children\u2019s Hospital, Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Izquierdo Anto","sequence":"additional","affiliation":[{"name":"Paediatrics Department, Hospital Sant Joan de D\u00e9u , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-2182","authenticated-orcid":false,"given":"Marta Taida","family":"Garc\u00eda Ascaso","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Department, Hospital Infantil Universitario del Ni\u00f1o Jes\u00fas , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-8164","authenticated-orcid":false,"given":"David","family":"D\u00edaz P\u00e9rez","sequence":"additional","affiliation":[{"name":"Paediatric Haemato-Oncology Department, Hospital Infantil Universitario del Ni\u00f1o Jes\u00fas , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-2024","authenticated-orcid":false,"given":"Carlos","family":"Grasa Lozano","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Department, Hospital Universitario La Paz , Madrid ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n del Hospital Universitario La Paz (IdiPAZ), Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n en Red Biom\u00e9dica en Enfermedades Infecciosas del Instituto de Salud Carlos III (CIBERINFEC) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1348-0401","authenticated-orcid":false,"given":"Cristina","family":"Jim\u00e9nez N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-1636","authenticated-orcid":false,"given":"Elena Mar\u00eda","family":"Rinc\u00f3n L\u00f3pez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red Biom\u00e9dica en Enfermedades Infecciosas del Instituto de Salud Carlos III (CIBERINFEC) , Madrid ,","place":["Spain"]},{"name":"Paediatric Infectious Diseases Unit, Gregorio Mara\u00f1\u00f3n General Hospital , Madrid ,","place":["Spain"]},{"name":"UDIMIFFA, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IISGM) , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-6936","authenticated-orcid":false,"given":"Maria Luisa","family":"Navarro G\u00f3mez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red Biom\u00e9dica en Enfermedades Infecciosas del Instituto de Salud Carlos III (CIBERINFEC) , Madrid ,","place":["Spain"]},{"name":"Paediatric Infectious Diseases Unit, Gregorio Mara\u00f1\u00f3n General Hospital , Madrid ,","place":["Spain"]},{"name":"UDIMIFFA, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IISGM) , Madrid, Spain"},{"name":"Departamento de Salud P\u00fablica y Materno-Infantil, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-436X","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Carazo Gallego","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies, Hospital Regional Universitario de M\u00e1laga , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4711-0616","authenticated-orcid":false,"given":"Beatriz","family":"\u00c1lvarez Vallejo","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies Unit, Children\u2019s Hospital, Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]},{"name":"Infection and Immunity in Pediatric Patients Research Group, Vall d\u2019Hebron Research Institute , Barcelona ,","place":["Spain"]},{"name":"Paediatric Infectious Diseases Unit, Paediatrics Department, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-4481","authenticated-orcid":false,"given":"Jose Tom\u00e1s","family":"Ramos Amador","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red Biom\u00e9dica en Enfermedades Infecciosas del Instituto de Salud Carlos III (CIBERINFEC) , Madrid ,","place":["Spain"]},{"name":"Departamento de Salud P\u00fablica y Materno-Infantil, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid ,","place":["Spain"]},{"name":"Paediatric Infectious Diseases Unit, Paediatrics Department, Instituto de Investigaci\u00f3n Sanitaria (i+12), Hospital 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4230-5035","authenticated-orcid":false,"given":"\u00c1ngela","family":"Manzanares","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Unit, Paediatrics Department, Instituto de Investigaci\u00f3n Sanitaria (i+12), Hospital 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-2941","authenticated-orcid":false,"given":"Beatriz","family":"Jim\u00e9nez Montero","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Unit, Paediatrics Department, Hospital Universitario Marqu\u00e9s de Valdecilla , Santander ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-0583","authenticated-orcid":false,"given":"Antoni","family":"Noguera Julian","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Systemic Inflammatory Response in Paediatrics, Paediatric Infectious Diseases Department, Institut de Recerca Sant Joan de D\u00e9u, Hospital Sant Joan de D\u00e9u , Barcelona ,","place":["Spain"]},{"name":"Centre for Biomedical Network Research on Epidemiology and Public Health (CIBERESP) , Madrid ,","place":["Spain"]},{"name":"Departament de Cirurgia i Especialitats Medicoquir\u00fargiques, Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0346-5570","authenticated-orcid":false,"given":"Pere","family":"Soler-Palacin","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies Unit, Children\u2019s Hospital, Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]},{"name":"Infection and Immunity in Pediatric Patients Research Group, Vall d\u2019Hebron Research Institute , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026011413262409400_dkaf394-B1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/INF.0b013e3181b076b1","article-title":"Invasive fungal infections in children","volume":"28","author":"Dornbusch","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"2026011413262409400_dkaf394-B2","doi-asserted-by":"publisher","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"issue":"6S Suppl 1","key":"2026011413262409400_dkaf394-B3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/INF.0000000000002317","article-title":"Management of invasive fungal disease in neonates and children","volume":"38","author":"Ferreras-Antol\u00edn","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2026011413262409400_dkaf394-B4","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1097\/INF.0000000000003659","article-title":"New developments in pediatric antifungal pharmacology","volume":"41","author":"Groll","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"2026011413262409400_dkaf394-B5","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/14787210.2016.1242413","article-title":"Diagnosis of invasive fungal diseases in pediatric patients","volume":"14","author":"Pana","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026011413262409400_dkaf394-B6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-Spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026011413262409400_dkaf394-B7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/myc.13622","article-title":"A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections","volume":"66","author":"Kato","year":"2023","journal-title":"Mycoses"},{"key":"2026011413262409400_dkaf394-B8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026011413262409400_dkaf394-B9","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026011413262409400_dkaf394-B10","doi-asserted-by":"publisher","first-page":"e01634-18","DOI":"10.1128\/AAC.01634-18","article-title":"Outcomes by MIC values for patients treated with isavuconazole or voriconazole for invasive Aspergillosis in the phase 3 SECURE and VITAL trials","volume":"63","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413262409400_dkaf394-B11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: Serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics"},{"key":"2026011413262409400_dkaf394-B12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"H\u00f6hl","year":"2022","journal-title":"Mycoses"},{"key":"2026011413262409400_dkaf394-B13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/jof6040192","article-title":"Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data","volume":"6","author":"Zhao","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026011413262409400_dkaf394-B14","doi-asserted-by":"publisher","first-page":"e0029021","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413262409400_dkaf394-B15","doi-asserted-by":"publisher","first-page":"e13855","DOI":"10.1111\/tid.13855","article-title":"Antifungal stewardship in solid organ transplantation","volume":"24","author":"Kriegl","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"2026011413262409400_dkaf394-B16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/ph15030375","article-title":"Isavuconazole treatment for invasive fungal infections in pediatric patients","volume":"15","author":"Zimmermann","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026011413262409400_dkaf394-B17","doi-asserted-by":"publisher","first-page":"e0082923","DOI":"10.1128\/aac.00829-23","article-title":"Isavuconazole use and TDM in real-world pediatric practice","volume":"67","author":"Fern\u00e1ndez Ledesma","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413262409400_dkaf394-B18","doi-asserted-by":"publisher","first-page":"e01783-19","DOI":"10.1128\/AAC.01783-19","article-title":"A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation","volume":"64","author":"Decembrino","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413262409400_dkaf394-B19","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3390\/microorganisms11092229","article-title":"Real-world, multicenter case series of patients treated with isavuconazole for invasive fungal disease in China","volume":"11","author":"Wu","year":"2023","journal-title":"Microorganisms"},{"key":"2026011413262409400_dkaf394-B20","doi-asserted-by":"publisher","first-page":"e00484-24","DOI":"10.1128\/aac.00484-24","article-title":"Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial","volume":"68","author":"Segers","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413262409400_dkaf394-B21","author":"European Medicines Agency"},{"key":"2026011413262409400_dkaf394-B22","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026011413262409400_dkaf394-B23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026011413262409400_dkaf394-B24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026011413262409400_dkaf394-B25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.anpedi.2023.11.016","article-title":"Therapeutic drug monitoring of antibiotic and antifungical drugs in paediatric and newborn patients. Consensus guidelines of the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Paediatric Infectious Diseases (SEIP)","volume":"101","author":"Luque","year":"2024","journal-title":"An Pediatr (Engl Ed)"},{"key":"2026011413262409400_dkaf394-B26","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026011413262409400_dkaf394-B27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/FTD.0000000000000980","article-title":"Real-world comparison of isavuconazole and voriconazole in terms of the need for dosage adjustments guided by clinical pharmacological advice during primary prophylaxis of invasive fungal infections in pediatric patients with hemato-oncological malignancies","volume":"44","author":"Gatti","year":"2022","journal-title":"Ther Drug Monit"},{"key":"2026011413262409400_dkaf394-B28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/jof9030387","article-title":"Mold-active antifungal prophylaxis in pediatric patients with cancer or undergoing hematopoietic cell transplantation","volume":"9","author":"Lehrnbecher","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2026011413262409400_dkaf394-B29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/INF.0000000000000101","article-title":"Role of management strategies in reducing mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem cell transplant: a single center 30-year experience","volume":"33","author":"Castagnola","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2026011413262409400_dkaf394-B30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/myc.13205","article-title":"Epidemiology of invasive fungal disease in haematologic patients","volume":"64","author":"Souza","year":"2021","journal-title":"Mycoses"},{"key":"2026011413262409400_dkaf394-B31","doi-asserted-by":"publisher","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2026011413262409400_dkaf394-B32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MPH.0000000000001787","article-title":"Safety of isavuconazonium sulfate in pediatrics patients with hematologic malignancies and hematopoietic cell transplantation with invasive fungal infections: a real world experience","volume":"42","author":"Ross","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026011413262409400_dkaf394-B33","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026011413262409400_dkaf394-B34","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1093\/jac\/dkad324","article-title":"Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube","volume":"78","author":"Bury","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026011413262409400_dkaf394-B35","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/INF.0000000000002671","article-title":"Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients","volume":"39","author":"Ashkenazi-Hoffnung","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2026011413262409400_dkaf394-B36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/pharmaceutics15010075","article-title":"Isavuconazole pharmacokinetics and pharmacodynamics in children","volume":"15","author":"Elhence","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026011413262409400_dkaf394-B37","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1097\/MPH.0000000000002812","article-title":"Characterization of the use and efficacy of isavuconazonium sulfate in a pediatric oncology and stem cell transplant population: a single institution retrospective review","volume":"46","author":"Kunvarjee","year":"2024","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf394\/64832343\/dkaf394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf394\/64832343\/dkaf394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:26:26Z","timestamp":1768415186000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf394\/8294483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf394","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,22]]},"article-number":"dkaf394"}}